GSK
762 hedge funds and large institutions have $9.69B invested in GSK in 2017 Q4 according to their latest regulatory filings, with 135 funds opening new positions, 168 increasing their positions, 348 reducing their positions, and 109 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
762
Holders Change
+22
Holders Change %
+2.97%
% of All Funds
17.31%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.2%
New
135
Increased
168
Reduced
348
Closed
109
Calls
$107M
Puts
$99.7M
Net Calls
+$7.16M
Net Calls Change
-$43.6M
Top Buyers
| 1 |
Dodge & Cox
San Francisco,
California
|
+$1.04B |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$599M |
| 3 |
Two Sigma Advisers
New York
|
+$64.3M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$53.2M |
| 5 |
Millennium Management
New York
|
+$46.8M |
Top Sellers
| 1 |
Wells Fargo
San Francisco,
California
|
-$190M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$120M |
| 3 |
HCM
Hamlin Capital Management
New York
|
-$72M |
| 4 |
MHI
Miller Howard Investments
Kingston,
New York
|
-$54.1M |
| 5 |
Morgan Stanley
New York
|
-$36.6M |
